Strategic planning for the development of a novel therapy is critically important to reduce financial burdens, save time, and find the best, shortest path forwards. No two products will have the same pathway or same criterion for optimisation, but early, forward-looking planning can result in greater efficiency and a better understanding of key decisions and timepoints along the course of novel therapy development.
Germany’s Curevac offers common shares
Latest NewsmRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market
Sponsored PublicationsBoth the US Skokie and European Rankweil sites address customer needs in early-phase drug development
BioSenic strengthens scientific team with new CSO
AppointmentsDr Carole Nicco took up her position as CSO of Belgium-based BioSenic in mid-January. Nicco will oversee the development of BioSenic’s cell therapy and autoimmune disease platform pipeline and be responsible for R&D programmes.
Chong Kun Dang Pharm licences Synaffix ADC platform
Latest NewsSouth Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BV’s propietary ADC platform.
New EU stakeholder platform to speed up clinical trials
Latest NewsA new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Biofilms for production
BackgroundResearchers have presented a novel method to promote biofilm formation. They believe their method can help to increase the efficiency of biocatalysis in biotechnological production processes and thus allow cost-effective recycling of waste, as well as carbon dioxide conversion into chemical building blocks and natural gas,
or amino acids.
Banks and policymakers driving climate change
BackgroundLast year, the G7 heads declared to end funding for the oil industry by the end of this year. At the COP27 in November, the WHO and United Nations renewed promises to redirect the hundreds of billions of dollars invested annually in fossil fuels to fund renewable energy initiatives.
Ultra-processed foods increase risk for cancer
Latest NewsBritish researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Lonza collaborates with Asher Biotherapeutics Inc
Latest NewsAsher Biotherapeutics Inc has expanded its manufacturing agreement with Lonza to include the manufacturing of AB248.
Wholistic approach to strategic consulting
BackgroundStrategic planning for the development of a novel therapy is critically important to reduce financial burdens, save time, and find the best, shortest path forwards. No two products will have the same pathway or same criterion for optimisation, but early, forward-looking planning can result in greater efficiency and a better understanding of key decisions and timepoints along the course of novel therapy development.